Dr Joshua D. Ooi

Dr. Ooi is an Al and Val Rosentrauss Fellow at Monash University. He specializes in the identification of autoimmune T cell epitopes and understanding the basis of autoimmune susceptibilities. He has shown that the frequencies of antigen specific regulatory T cells are a key determinant for protection from autoimmune disease. Alongside mentor Prof. Richard Kitching, Dr. Ooi received his first NHMRC Project Grant in 2018 to develop therapeutic strategies using antigen specific regulatory T cells.

David Kavanagh

Professor of Complement Therapeutics, Honorary Consultant Nephrologist, National Renal Complement Therapeutics Centre, UK.

David Kavanagh is the Professor of Complement Therapeutics at the National Renal Complement Therapeutics Centre (NRCTC). He is the clinical lead for the adult aHUS service and head of aHUS diagnostics service. His University research group investigates the role of complement in renal and retinal diseases and is fully integrated with the NRCTC to provide rapid translational benefits to patients.

He moved to Newcastle to start his own lab in 2008 with a Wellcome Trust Fellowship following a Kidney Research UK Fellowship at the University of Edinburgh. He was previously a Fellow at Washington University School of Medicine, St. Louis. He graduated in Medicine and Immunology from the University of Glasgow in 1998 and obtained his PhD from Newcastle University in 2006. For his work defining the role of complement in aHUS, he was awarded the Renal Association’s Young Investigator (Raine) award.

Angela Webster

Angela is a Nephrologist and Transplant Physician, having trained in England, Scotland and Australia. She studied Clinical Epidemiology at the University of Sydney, and was awarded a PhD for her thesis Immunosuppression and malignancy in End Stage Kidney Disease in 2006. She now splits her time working as a Staff Specialist in Renal Medicine and Transplantation at Westmead Hospital and as an Associate Professor in Clinical Epidemiology in the Sydney School of Public Health. She is the Executive Officer of the Australian and New Zealand Islet and Pancreas Transplant Registry, a member of the Australia and New Zealand Dialysis and Transplant registry (ANZDATA) Cancer working group and of the New South Wales Transplant Advisory Committee. She is Chair of the Scientific Program and Education Committee (SPEC) of the Australian and New Zealand Society of Nephrology. Angela is funding arbiter for Cochrane, and from 2007-2015 was deputy coordinating editor of the Cochrane Kidney and Transplant, where she remains an Editor.

Angela’s areas of research interest include the critical exploration of randomized trial methodology, the evaluation of diagnostic tests in clinical practice, the application of advanced statistical concepts in meta-analysis, the manipulation and analysis of large datasets, the methods and application of linkage of large national databases, and design and interpretation of cohort studies. She has an interest in research integrity in biomedical publishing.

Her research themes include the interaction of chronic diseases, specifically chronic kidney disease, with cancer and with cardiovascular disease including stroke. She has an interest in the cognitive effects of chronic diseases, and the impact this has on health. She is interested in ways to promote self-management to help people live well with chronic disease

Kate Wyburn

Kate Wyburn is a full time Senior Staff Specialist Nephrologist and Director of Kidney Transplantation at The Royal Prince Alfred Hospital Sydney, the current Chair of the NSW Transplant Advisory Committee and member of the National Renal Transplant Advisory Committee. She is the Chair of The Solid Organ Transplantation working group of The National IVIG Governance Advisory Committee for the National Blood Authority Australia. She has been a Senior Lecturer at The University of Sydney since 2007 and a Clinical Associate Professor since 2013.  She undertook her PhD at Sydney University and was an NH&MRC PhD scholar. She is a member of The Kidney Node at The Charles Perkins Centre at The University of Sydney and her current areas of research include antibody mediated rejection and donor specific antibodies, blood group incompatible transplantation, and organ donation suitability.

Katherine Barraclough

Katherine Barraclough is a Consultant Nephrologist at the Royal Melbourne Hospital. She completed her basic medical training in Melbourne then undertook advanced training in Nephrology in Vancouver, Canada, New Delhi India and Brisbane, Australia. She subsequently completed a PhD through the University of Queensland (2012) undertaking clinical research examining pharmacogenetic, pharmaocokinetic and pharmaocdynamic monitoring of immunosuppressive therapy in adult kidney transplant recipients.

Over the years her primary research interests have included individualization of immunosuppression in kidney transplantation and Indigenous Australian renal health and disease. More recently, she has focused her attention on the issue of environmental sustainability within the health care system and the intersection between planetary and human health. She is current Chair of the Victorian Nephrology Environmental Sustainability Special Interest Group and the ANZSN Green Nephrology Working Group. She is also a committee member of the Victorian branch for Doctors for the Environment.

Dr Tom Barbour

Dr Tom Barbour graduated in Medicine in 2004 at the University of Sydney, where he had previously obtained an Arts degree with honours in classical languages.  He was a specialist trainee in nephrology at Royal Melbourne Hospital and at the Churchill Hospital, Oxford, UK, and received his Fellowship of the Royal Australasian College of Physicians in 2012.  He was awarded a Kidney Research UK Fellowship in 2011, enabling him to undertake a PhD in Medicine at Imperial College, London.  There, he was based at the Centre for Complement and Inflammation Research (CCIR) at Hammersmith Hospital.

 

His research examined the role of the complement system (an immune defense system) in kidney diseases including C3 glomerulopathy (a type of glomerulonephritis).  Specifically, he worked on an animal model of C3 glomerulopathy in mice with genetic deficiency of complement factor H.  He has co-authored a number of publications on topics including C3 glomerulopathy, atypical haemolytic uraemic syndrome (aHUS) and thrombotic microangiopathy after renal transplantation.

In 2015 he was appointed as a nephrologist to the Royal Melbourne Hospital, where he also plans to continue his research in the field of complement-mediated kidney diseases.

Adrian Liew

Dr Adrian Liew is a Senior Consultant and Chief of Nephrology at the Department of Renal Medicine, Tan Tock Seng Hospital in Singapore. He is an Associate Professor of Medicine and is the Renal Curriculum Lead with the Lee Kong Chian School of Medicine at the Imperial College London-Nanyang Technological University. He serves in his professional capacity as a Senior Consultant with the Ministry of Health, Singapore and is a member of various national advisory committees. He is responsible for the implementation of various renal related initiatives in Singapore, including the national HALT-CKD program and the Peritoneal Dialysis Preferred Policy. Dr Liew is an elected council member of the International Society of Nephrology, and has also been elected as a Fellow to various academic institutions including the Royal College of Physicians in United Kingdom, American Society of Nephrology and the Academy of Medicine, Singapore. He is the National Leader for various multicentre clinical trials, and has research interests in glomerular diseases, renal immunology and peritoneal dialysis. He has also been actively involved in the training and development of glomerular disease and peritoneal dialysis programs in various countries in Southeast Asia and has provided sister renal centre mentorship to nephrologists in several developing countries.

 

Sydney Tang

Sydney Tang graduated from the University of Hong Kong and has obtained MD and PhD degrees at the University of Hong Kong. He has undergone training in basic science research in nephrology at Guy’s Hospital, King’s College London, and Seattle Children’s Hospital, University of Washington. He is currently Chair Professor of Renal Medicine and Yu Endowed Professor in Nephrology at The University of Hong Kong. His research interests range from basic to clinical sciences including the role of renal tubular cells in diabetic and proteinuric nephropathies, and the treatment of IgA nephropathy. He has published over 200 journal articles and 25 textbook chapters, edited one book, and is on the Editorial Boards of a number of nephrology journals including Kl, CJASN, NDT, American Journal of Nephrology, Nephrology, and Journal of Nephrology. He serves the Hong Kong College of Physicians as Chairman for Basic Training, and the Royal College of Physicians of Edinburgh as International Advisor. He is currently Chairman of the Hong Kong Society of Nephrology, Executive member of the Asian Pacific Society of Nephrology, and the North and East Asia Regional Board of the International Society of Nephrology. He is also on the Meetings Committee of the International Society of Nephrology. He has been invited to deliver lectures at many national and international meetings including the American Society of Nephrology Kidney Week and the World Congress of Nephrology.

Angela Wang

Angela Yee Moon Wang, MD, PhD, FRCP, is a Clinician Scientist working at the Queen Mary Hospital, University of Hong Kong, Hong Kong and was graduated from the University of New South Wales, Australia.

She is the recipient of this year United States National Kidney Foundation Joel D. Kopple Award. She also received the John Maher Award of the International Society of Peritoneal Dialysis (ISPD) in 2006, Travelling Lecturer Award of Asian and Pacific Federation of Clinical Biochemistry in 2012.

 

Angela is currently the President of the International Society of Renal Nutrition and Metabolism (ISRNM) and Council member of the ISPD. She is also a North and East Asia Regional Board member of the International Society of Nephrology (ISN), Committee Member of the ISN-Advancing Clinical Trial Core Group, and Executive Committee member of the Standardized Outcomes in Nephrology (SONG) Initiative, workgroup member of the SONG-PD and SONG-HD CVD. She was an Executive Committee Member of KDIGO (Jan 2015 – Dec 2017).

She is a workgroup member of the NKF Kidney Disease Outcome Quality Initiative (KDOQI) Nutrition Guidelines in CKD (to be published in 2018/2019) and the ISPD PD Adequacy Guideline update (2017-2019). She chaired the ISPD Adult Cardiovascular and Metabolic Guidelines (2012 – 2015) and is a Subcommittee Chair of the ISPD PDOPPS. She was also a Core workgroup member of the first KDIGO – CKD-MBD guidelines (2007 – 2009).

She is a member of the Scientific Program Committee of WCN 2019 in Melbourne and co-Chairs the Renal Nutrition, Nurses and Allied Health Symposium at the WCN 2019. She also co-Chairs the upcoming ISN Frontiers Meeting 2019.

Angela serves on the editorial board of several journals: JASN, CJASN, NDT (Editor of Cardiovascular Section), Am J Nephrol, Nephron Clin Pract (Associate Editor), European Medical Journal (EMJ)-Nephrology (Editor-in-Chief), Renal Replacement Therapy (Associate Editor), Nephrology (Subject Editor), J Ren Nutr, J Diabetes, Blood Purification, Biomedicine Hub, etc. She was previously an Associate Editor of AJKD and an International Editor of CJASN.

She has given over 100 invited lectures around the world and is a key opinion leader in clinical research relating to CKD and dialysis complications, especially in the areas of cardiovascular disease, heart failure, vascular calcification, CKD-MBD, diet and nutrition as well as residual kidney function in PD. She is the Principal Investigator of OPERA Trial, CASCADE study, and the PROOF Trial.

Barbara Murphy

Barbara Murphy, MB, BAO, BCh, FRCPI, is the Chair of the Samuel Bronfman Department of Medicine, the Murray M. Rosenberg Professor of Medicine, and the Dean of Clinical Integration and Population Management at the Icahn School of Medicine at the Mount Sinai Health System. Dr. Murphy earned her medical degree from The Royal College of Surgeons in Ireland. She did her clinical training in internal medicine and fellowship in clinical nephrology at Beaumont Hospital, Dublin and completed her postdoctoral training in nephrology and transplant immunology at Brigham and Women’s Hospital, Harvard Medical School. She was recruited to Mount Sinai as Director of Transplant Nephrology, where she was subsequently named Chief of the Division of Nephrology in and then Chair of Medicine in 2012. At a national level Dr. Murphy has held many leadership positions in the American Society of Transplantation and American Society of Nephrology including being a past President of the American Society of Transplantation and most recently she was elected to ASN council.

Dr Murphy’s research focuses on the use of high throughput genomic technologies as a means to understand the immune mechanisms that lead to graft injury and loss, with the aim of identifying gene expression profiles and genetic variants that may be used to predict outcomes post transplantation. Work lead by Dr Murphy, as part of a large collaborative study (GoCAR), has identified a peripheral expression gene profile that diagnoses subclinical acute rejection and stratifies patients based on immunological risk, and demonstrated that expression within the graft early post transplant identifies patients at greatest risk for fibrosis and graft loss

KEYNOTE:  Mechanisms and genomics of progressive renal fibrosis in CKD and renal allograft nephropathy
SEMINAR 5: Immune stratification

About ANZSN

The ASM is hosted by Australian and New Zealand Society of Nephrology.

The aims of the Society are to promote and support the study of the kidney and urinary tract in health and disease, and to ensure the highest professional standards for the practice of nephrology in Australia and New Zealand.

Conference Managers

Please contact the team at Conference Design with any questions regarding the Annual Scientific Meeting

© 2015 - 2016 Conference Design Pty Ltd